SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) — Countless Genetics, Inc. (NASDAQ:MYGN), a baton in atomic affection and alone medicine, today appear that Virginia (“Gina”) C. Drosos, admiral of Assurex Health, a wholly-owned accessory of Countless Genetics, has accustomed the EY Entrepreneur of the Year accolade for bloom affliction casework in the Ohio Valley Region. The awards affairs recognizes entrepreneurs who excel in innovation, banking achievement and claimed charge to their businesses and communities. Accolade winners accept congenital some of the world’s best constant companies, before U.S. bazaar achievement in agreement of acquirement growth, job conception and longevity.
“We congratulate Gina on her outstanding accomplishment. Her abstracted administration has congenital Assurex Bloom into one of the best acknowledged and fastest growing alone anesthetic companies in history,” said Mark C. Capone, admiral and CEO of Countless Genetics. “Under her leadership, the avant-garde GeneSight® analysis has been acclimated by over 19,000 healthcare professionals to advice advance the lives of added than 500,000 patients adversity from abasement and added brainy bloom disorders.”
Gina aing Assurex Bloom in 2013. Previously, she managed a $6 billion dollar all-around cast portfolio in the customer appurtenances and claimed affliction industries at Procter & Gamble for 25 years. She holds a B.S. in Business Administration from The Terry School, University of Georgia, and an M.B.A. from The Wharton School, University of Pennsylvania.
About The GeneSight® TestThe GeneSight analysis helps healthcare providers accomplish bigger analysis decisions based on a person’s abiogenetic makeup. GeneSight testing is based on avant-garde CPGx® technology, a patented access that analyzes variations and combinations of a person’s genes forth with FDA-approved medications for behavioral bloom altitude and abiding pain. Peer-reviewed, appear studies accept accurate its analytic allowances and abundant healthcare amount savings. Added than 19,000 healthcare professionals accept acclimated GeneSight with over 500,000 patients. Learn added at www.GeneSight.com.
About Assurex HealthAssurex Health, a wholly-owned accessory of Countless Genetics, Inc., is an informatics-based, alone anesthetic aggregation accouterment analysis accommodation abutment to healthcare providers for behavioral bloom and abiding affliction conditions. Assurex Bloom is the alone aggregation in the class with assorted peer-reviewed, appear studies that authenticate the analytic authority and analytic account of the GeneSight® test, including its abundant healthcare amount accumulation benefit. The Aggregation has developed every division and has broadcast internationally through a affiliation with Canada’s Centre for Addiction and Brainy Bloom (CAMH). For added on how Assurex Bloom is allowance bodies accretion brainy wellness, appointment www.AssurexHealth.com.
About Countless GeneticsMyriad Genetics Inc., is a arch alone anesthetic aggregation committed to actuality a trusted adviser transforming accommodating lives common with beat atomic diagnostics. Countless discovers and commercializes atomic analytic tests that: actuate the accident of developing disease, accurately analyze disease, appraise the accident of ache progression, and adviser analysis decisions beyond six above medical specialties area atomic affection can decidedly advance accommodating affliction and lower healthcare costs. Countless is focused on three cardinal imperatives: transitioning and accretion its ancestral blight testing markets, diversifying its artefact portfolio through the addition of new articles and accretion the acquirement addition from all-embracing markets. For added advice on how Countless is authoritative a difference, amuse appointment the Company’s website: www.myriad.com.
Myriad, the Countless logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Countless myRisk, myRisk Ancestral Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Countless Genetics, Inc. or its wholly endemic subsidiaries in the United States and adopted countries. MYGN-F, MYGN-G.
Safe Harbor Statement This columnist absolution contains “forward-looking statements” aural the acceptation of the Clandestine Securities Litigation Reform Act of 1995, including statements apropos to Assurex Bloom actuality one best acknowledged and fasted growing alone anesthetic companies in history; the adeptness of the GeneSight analysis to advice advance affliction for bodies with abasement or added brainy bloom disorders; and the Company’s cardinal directives beneath the explanation “About Countless Genetics.” These “forward-looking statements” are based on management’s accepted expectations of approaching contest and are accountable to a cardinal of risks and uncertainties that could account absolute after-effects to alter materially and abnormally from those declared or adumbrated in the advanced statements. These risks include, but are not bound to: the accident that sales and accumulation margins of our absolute atomic analytic tests and biologic and analytic casework may abatement or will not abide to access at actual rates; risks accompanying to our adeptness to alteration from our absolute artefact portfolio to our new tests; risks accompanying to changes in the authoritative or clandestine insurers’ agreement levels for our tests or our adeptness to access agreement for our new tests at commensurable levels to our absolute tests; risks accompanying to added antagonism and the development of new aggressive tests and services; the accident that we may be clumsy to advance or accomplish bartering success for added atomic analytic tests and biologic and analytic casework in a appropriate manner, or at all; the accident that we may not auspiciously advance new markets for our atomic analytic tests and biologic and analytic services, including our adeptness to auspiciously accomplish acquirement alfresco the United States; the accident that licenses to the technology basal our atomic analytic tests and biologic and analytic casework tests and any approaching tests are concluded or cannot be maintained on satisfactory terms; risks accompanying to delays or added problems with operating our class testing facilities; risks accompanying to accessible affair over our abiogenetic testing in accepted or our tests in particular; risks accompanying to authoritative requirements or administration in the United States and adopted countries and changes in the anatomy of the healthcare arrangement or healthcare acquittal systems; risks accompanying to our adeptness to access new accumulated collaborations or licenses and access new technologies or businesses on satisfactory terms, if at all; risks accompanying to our adeptness to auspiciously accommodate and access allowances from any technologies or businesses that we authorization or acquire, including but not bound to our accretion of Assurex, Sividon and the Clinic; risks accompanying to our projections about the abeyant bazaar befalling for our products; the accident that we or our licensors may be clumsy to assure or that third parties will borrow the proprietary technologies basal our tests; the accident of patent-infringement claims or challenges to the authority of our patents; risks accompanying to changes in bookish acreage laws accoutrement our atomic analytic tests and biologic and analytic casework and patents or administration in the United States and adopted countries, such as the Supreme Court accommodation in the accusation brought adjoin us by the Association for Atomic Pathology et al; risks of new, alteration and aggressive technologies and regulations in the United States and internationally; the accident that we may be clumsy to accede with banking operating covenants beneath our acclaim or lending agreements; the accident that we will be clumsy to pay, back due, amounts due beneath our acclaim or lending agreements; and added factors discussed beneath the branch “Risk Factors” independent in Item 1A of our Annual address on Form 10-K for the budgetary year concluded June 30, 2016, which has been filed with the Securities and Exchange Commission, as able-bodied as any updates to those accident factors filed from time to time in our Quarterly Reports on Form 10-Q or Accepted Reports on Form 8-K.
Georgia Advance Directive Form 11 Is So Famous, But Why? | Georgia Advance Directive Form 11 – georgia advance directive form 2017
| Welcome to our website, in this particular time period I will show you about georgia advance directive form 2017